Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of rCSP/AP 10-602 Malaria Vaccine in Healthy Adults
NCT03589794Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2018
- Primary completion
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of rCSP in malaria (7 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Adverse Events of Special Interest, Serious Adverse Events and 2 more. Started Dec 2018; status: completed.
02
Drugs
rCSP
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03589794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03589794.